JAGUAR HEALTH, INC. Net Income (Loss) Attributable to Noncontrolling Interest
JAGUAR HEALTH, INC. (JAGX) reported Net Income (Loss) Attributable to Noncontrolling Interest of -$120.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2026-08-19
- JAGUAR HEALTH, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$120.00K.
- JAGUAR HEALTH, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$126.00K.
- JAGUAR HEALTH, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$132.00K.
- JAGUAR HEALTH, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$146.00K.
- JAGUAR HEALTH, INC. net income (loss) attributable to noncontrolling interest for fiscal 2025 was -$563.00K.
- JAGUAR HEALTH, INC. net income (loss) attributable to noncontrolling interest for fiscal 2024 was -$759.00K.
- JAGUAR HEALTH, INC. net income (loss) attributable to noncontrolling interest for fiscal 2023 was -$601.00K.
- JAGUAR HEALTH, INC. net income (loss) attributable to noncontrolling interest for fiscal 2022 was -$941.00K.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$120.00K 10-Q · filed 2026-08-19 | -$246.00K 10-Q · filed 2026-08-19 | -$378.00K derived: sum of 3 quarters · filed 2026-08-19 | -$524.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | -$126.00K 10-Q · filed 2026-05-20 | -$258.00K derived: sum of 2 quarters · filed 2026-05-20 | -$404.00K derived: sum of 3 quarters · filed 2026-05-20 | -$557.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | -$132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | -$278.00K derived: sum of 2 quarters · filed 2026-04-07 | -$431.00K derived: sum of 3 quarters · filed 2026-08-19 | -$563.00K 10-K · filed 2026-04-07 |
| 2025-09-30 | -$146.00K 10-Q · filed 2025-11-14 | -$299.00K derived: sum of 2 quarters · filed 2026-08-19 | -$431.00K 10-Q · filed 2025-11-14 | -$745.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | -$153.00K 10-Q · filed 2026-08-19 | -$285.00K 10-Q · filed 2026-08-19 | -$599.00K derived: sum of 3 quarters · filed 2026-08-19 | -$766.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | -$132.00K 10-Q · filed 2026-05-20 | -$446.00K derived: sum of 2 quarters · filed 2026-05-20 | -$613.00K derived: sum of 3 quarters · filed 2026-05-20 | -$749.00K derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | -$314.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | -$481.00K derived: sum of 2 quarters · filed 2026-04-07 | -$617.00K derived: sum of 3 quarters · filed 2026-04-07 | -$759.00K 10-K · filed 2026-04-07 |
| 2024-09-30 | -$167.00K 10-Q · filed 2025-11-14 | -$303.00K derived: sum of 2 quarters · filed 2025-11-14 | -$445.00K 10-Q · filed 2025-11-14 | -$584.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$136.00K 10-Q · filed 2025-08-14 | -$278.00K 10-Q · filed 2025-08-14 | -$417.00K derived: sum of 3 quarters · filed 2025-08-14 | -$543.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$142.00K 10-Q · filed 2025-05-15 | -$281.00K derived: sum of 2 quarters · filed 2025-05-15 | -$407.00K derived: sum of 3 quarters · filed 2025-05-15 | -$548.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$139.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$265.00K derived: sum of 2 quarters · filed 2025-03-31 | -$406.00K derived: sum of 3 quarters · filed 2025-03-31 | -$601.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | -$126.00K 10-Q · filed 2024-11-13 | -$267.00K derived: sum of 2 quarters · filed 2024-11-13 | -$462.00K 10-Q · filed 2024-11-13 | -$1.11M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$141.00K 10-Q · filed 2024-08-13 | -$336.00K 10-Q · filed 2024-08-13 | -$987.00K derived: sum of 3 quarters · filed 2024-08-13 | -$1.08M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$195.00K 10-Q · filed 2024-05-14 | -$846.00K derived: sum of 2 quarters · filed 2024-05-14 | -$935.00K derived: sum of 3 quarters · filed 2024-05-14 | -$958.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$651.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$740.00K derived: sum of 2 quarters · filed 2024-04-01 | -$763.00K derived: sum of 3 quarters · filed 2024-04-01 | -$941.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | -$89.00K 10-Q · filed 2023-11-14 | -$112.00K derived: sum of 2 quarters · filed 2023-11-14 | -$290.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | -$23.00K 10-Q · filed 2023-08-14 | -$201.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | -$178.00K 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | -$5.00K 10-K · filed 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |